ASLAN Pharmaceuticals Limited (ASLN)
Stock Price:
$1.98 USD
-0.02 (-1.00%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
75.22M |
| Revenue (ttm) |
3.00M |
| Net Income (ttm) |
-47.07M |
| Shares Out |
37.99M |
| EPS (ttm) |
-0.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$1.98 |
| Previous Close |
$2.00 |
| Change ($) |
-0.02 |
| Change (%) |
-1.00% |
| Day's Open |
1.99 |
| Day's Range |
1.98 - 2.05 |
| Day's Volume |
41,071 |
| 52-Week Range |
0.35 - 8.18 |
More Stats
| Market Cap |
75.22M |
| Enterprise Value |
71.67M |
| Earnings Date (est) |
Aug 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.99M |
| Float |
36.90M |
| EPS (basic) |
-0.29 |
| EPS (diluted) |
-0.86 |
| FCF / Share |
-0.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
45,709 |
| Short Ratio |
0.49 |
| Short % of Float |
n/a |
| Beta |
1.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
25.07 |
| PB Ratio |
6.05 |
| Revenue |
3.00M |
| Operating Income |
-45.58M |
| Net Income |
-47.07M |
| Free Cash Flow |
-25.51M |
| Net Cash |
3.55M |
| Net Cash / Share |
0.09 |
| Gross Margin |
2,660.70% |
| Operating Margin |
-1,519.30% |
| Profit Margin |
-1,568.90% |
| FCF Margin |
-850.21% |
| ROA |
-41.96% |
| ROE |
-408.12% |
| ROIC |
-430.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.50*
(177.78% upside)
Low
5.00
Current: 1.98
High
6.01
Target: 5.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 3.00 | - | - | 11.55 |
| Gross Profit | 2.59 | - | - | 11.42 |
| Operating Income | -45.58 | -42.35 | -39.14 | -8.70 |
| Net Income | -47.07 | -42.19 | -39.89 | -9.05 |
| Shares Outstanding | 160 | 168 | 168 | - |
| Earnings Per Share | -0.29 | -0.28 | -0.32 | -0.09 |
| Operating Cash Flow | -25.51 | -39.72 | -34.48 | -5.80 |
| Capital Expenditures | - | -23.08 | -0.30 | -0.46 |
| Free Cash Flow | -25.51 | -62.81 | -34.78 | -6.25 |
| Cash & Equivalents | 22.20 | 28.91 | 50.57 | 51.74 |
| Total Debt | 18.65 | 13.97 | 9.68 | 8.34 |
| Net Cash / Debt | 3.55 | 14.93 | 40.89 | 43.40 |
| Assets | 23.35 | 52.88 | 51.33 | 53.71 |
| Liabilities | 23.95 | 22.26 | 15.82 | 12.14 |
| Book Value | -1.68 | 30.62 | 35.51 | 41.57 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ASLAN Pharmaceuticals Limited |
| Country |
Singapore |
| CEO |
Carl Aslan Jason Morton Firth |
Stock Information
| Ticker Symbol |
ASLN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ASLN |
| IPO Date |
May 4, 2018 |
Description
ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical company in the United States. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor (HER), inhibitor that targets the human epidermal growth factor receptors HER1, and HER2, as well as gastric cancer. Its Varlitinib completed a pivotal clinical trial for biliary tract cancer. In addition, the company is developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase II clinical trials to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. Further, the company has rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. ASLAN Pharmaceuticals Limited has licensing agreement with Bristol-Myers Squibb, Almirall, CSL Limited, Hyundai Pharm Co., Ltd., and BioGenetics Co. Ltd.; and licensing and research collaboration agreement with Nanyang Technological University. The company was founded in 2010 and is headquartered in Singapore.